| Name | Title | Contact Details |
|---|
We are bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to our lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). We bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers. We are bold in our mission and purpose and aim for nothing less than a transformative impact on people`s lives.
Areteia Therapeutics (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia`s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to establish Areteia and advance dexpramipexole through Phase 3 clinical trials, secure commercial supply, and pursue potential next-generation medicines. Areteia will conduct late-stage development including Phase 3 clinical trials of dexpramipexole in partnership with Population Health Partners` development unit, Validae Health.
As a leader in precision oncology, Fore Biotherapeutics provides patients with unaddressed cancer mutations new hope by connecting them with hyper-targeted medicines. Fore`s integrated functional genomics and machine learning capabilities, known as Foresight, are elucidating disease biology in competitively distinct and unparalleled ways that allow us to uniquely identify clinical-stage assets for people with few to no therapeutic alternatives. Fore is advancing its lead program, FORE8394, to treat both V600 and non-V600 BRAF mutations and continues to refine its clinical approach to serve more patient populations with difficult-to-treat mutations across oncogenes.
Eurofins is a Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cyagra Inc is a Elizabethtown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.